- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Elisabet Manasanch: As Data Build on Effectiveness of MRD Testing, Adherence Will Increase
Although it is true that there are people who still don't use minimal residual disease (MRD) testing, I think that its use is going to pick up based on results of emerging clinical studies, said Elisabet Manasanch, MD, assistant professor in the Department of Lymphoma/Myeloma and Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
Although it is true that there are people who still don't use minimal residual disease (MRD) testing, I think that its use is going to pick up based on results of emerging clinical studies, said Elisabet Manasanch, MD, assistant professor in the Department of Lymphoma/Myeloma and Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
Transcript
How widely should MRD testing be occuring? It’s not happening everywhere, but should it be?
Well, as with all new things in medicine, it takes a little bit to break through. So, people have been talking about minimal residual disease in myeloma for 10 years, but we do have more and more data showing that it does correlate with our clinical outcomes. So, it's not been until very recently, probably the last couple of years, 2 to 3 years that we've had actually major studies that have used minimal residual disease testing in their outcomes showing that the patients that are negative do better than the ones that are positive, so this is very, very recent. Although it is true there are people who still don't use it, I think that the use is going to pick up just because every time we have more and more data.
There are presentations here about that, there’s a presentation of another meta-analysis that was published here a couple years ago—it's being updated with more follow-up and showing the same thing that it predicts how long once your negative. If you're negative, your interval free of myeloma will be longer than if you're positive, for example. Also, how long you survive with this disease will also be longer if you're negative than positive. This is just confirming these things. So, I think that some of the barriers are basically just making people aware, making patients aware, making physicians in the community aware that this is a test that is available. Especially commercially, if they do not have access to a test that they can do at, for example, an economic center.
In this interview with The American Journal of Managed Care®, Katie Queen, MD, addresses the complexity of obesity as a medical condition, pivoting to virtual care while ensuring that patients who lived in a rural location continued to receive adequate care, and the importance of integrating awareness of obesity and chronic disease prevention into local food culture.
Read More
Recent T1D Research Contradicts Common Assumptions About Patients
November 15th 2023Michael Fang, PhD, researcher and assistant professor in the division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University, discussed recent findings in the type 1 diabetes (T1D) space that may alter the way providers address diabetes diagnoses.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
